文献速递胸部肿瘤

靶向NFE2L2/KEAP1突变晚期非小细胞肺癌:TORC1/2抑制剂TAK-228研究

Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
PubMed 文献 · J Thorac Oncol · 2022-10-12

在携带NRF2激活改变的晚期非小细胞肺癌患者中开展TAK-228的2期临床试验,设三个队列。TAK-228在NFE2L2突变肺鳞癌队列中总体缓解率为25%,中位无进展生存期为8.9个月。结论认为TAK-228在NRF2激活的肺鳞癌中具有单药活性。

要点

  • TAK-228在NFE2L2突变肺鳞癌队列中总体缓解率为25%。
  • 该队列中位无进展生存期为8.9个月。
  • 临床前数据提示CB-839抑制谷氨酰胺酶可能克服代谢耐药。

核心结论

  • TAK-228在NRF2激活的肺鳞癌患者中具有单药活性。
  • 本研究将致癌改变基于其对代谢的下游效应重新定义为生物学相关。
  • 该试验为首次成功尝试以代谢为靶点治疗非小细胞肺癌,并为缺乏基因型导向治疗的肺鳞癌患者确定了一种有前景的靶向治疗。

研究设计与样本

  • 研究描述了TAK-228在携带NRF2激活改变的NSCLC模型中的特异性强效活性。
  • 开展了一项TAK-228的2期临床试验,纳入携带NRF2激活改变的晚期NSCLC患者。
  • 试验设三个队列:NFE2L2突变肺鳞癌、KEAP1突变肺鳞癌、KRAS/NFE2L2或KEAP1突变NSCLC。

主要发现

  • TAK-228在NFE2L2改变肺鳞癌队列中最为有效,总体缓解率为25%。
  • 该队列中位无进展生存期为8.9个月。
  • 额外数据提示,联合谷氨酰胺酶抑制剂CB-839可能克服这些患者的代谢耐药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Increased insight into the mutational landscape of squamous cell lung cancers (LUSCs) in the past decade has not translated into effective targeted therapies for patients with this disease. NRF2, encoded by NFE2L2, and its upstream regulator, KEAP1, control key aspects of redox balance and are frequently mutated in NSCLCs. METHODS: Here, we describe the specific potent activity of TAK-228, a TORC1/2 inhibitor, in NSCLC models harboring NRF2-activating alterations and results of a phase 2 clinical trial of TAK-228 in patients with advanced NSCLC harboring NRF2-activating alterations including three cohorts (NFE2L2-mutated LUSC, KEAP1-mutated LUSC, KRAS/NFE2L2- or KEAP1-mutated NSCLC). RESULTS: TAK-228 was most efficacious in a LUSC cohort with NFE2L2 alterations; the overall response rate was 25% and median progression-free survival was 8.9 months. Additional data suggest that concurrent inhibition of glutaminase with the glutaminase inhibitor CB-839 might overcome metabolic resistance to therapy in these patients. CONCLUSIONS: TAK-228 has single-agent activity in patients with NRF2-activated LUSC. This study reframes oncogenic alterations as biologically relevant based on their downstream effects on metabolism. This trial represents, to the best of our knowledge, the first successful attempt at metabolically targeting NSCLC and identifies a promising targeted therapy for patients with LUSC, who are bereft of genotype-directed therapies.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Paik PK, Fan PD, Qeriqi B, et al. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228. J Thorac Oncol. 2022. PMID: 36240971. doi:10.1016/j.jtho.2022.09.225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。